EXPLOITING NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA (K23M)

探索多发性骨髓瘤 (K23M) 的新治疗靶点

• 批准号: 6917306
• 负责人: RUBEN NIESVIZKY
• 金额: $ 13.61万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-02 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6917306
• 关键词: amidohydrolases; antineoplastics; apoptosis; cell growth regulation; cell line; clarithromycin; clinical research; clinical trial phase II; combination chemotherapy; dexamethasone; drug screening /evaluation; enzyme inhibitors; experimental designs; genetic regulation; genetic transcription; human subject; human therapy evaluation; immunocytochemistry; microarray technology; multiple myeloma; neoplasm /cancer chemotherapy; neoplastic cell; patient oriented research; pharmacokinetics

DESCRIPTION (provided by applicant): Development of novel therapeutic strategies in myeloma and other B-cell malignancies requires collaborative efforts between clinical researchers and basic scientists. There is a clear need for individuals with skills in patients care, clinical trial design, and basic science principles who can bridge the gap between the bench and the bedside in the conception, development and evaluation of new treatment in these and other forms of cancer. As the principal investigator in this project, Dr Niesvizky is dedicated to further his research activities and undergo further mentored training for his career development to fill this long-term role. In order to attain the necessary skills, the strategy is to follow an educational and research path including: 1) Development and execution of a translational study to evaluate the effect of selected promising agents in the treatment of multiple myeloma under the tutoring of Drs. Bergsagel and Chen-Kiang. 2) Didactic and mentored training in clinical trial design with Dr Scott Wadler, as well as through several institutional resources including the General Clinical Research Center and the Weill Graduate School of Medical Sciences of Cornell University. 3)Development and execution of investigator-initiated clinical trials for myeloma using novel agents and combinations. Dr Niesvizky's research is focused in drug development. Following this five-year comprehensive program, he will attain the independent clinical research skills to work with basic science collaborators to lead a translational research program in drug development and other novel treatments for myeloma. It is expected that this work will significantly contribute to the care of patients with this disease and other B-cell malignancies.

描述（由申请人提供）：开发骨髓瘤和其他B细胞恶性肿瘤的新型治疗策略需要临床研究人员和基础科学家之间的合作。 有一个明确的需要个人的技能，在病人护理，临床试验设计，和基本的科学原则谁可以弥合之间的差距差距的板凳和床旁的概念，开发和评估新的治疗方法在这些和其他形式的癌症。 作为该项目的首席研究员，Niesvizky博士致力于进一步开展研究活动，并接受进一步的职业发展指导培训，以填补这一长期角色。 为了获得必要的技能，战略是遵循教育和研究的道路，包括： 1)在Bergsagel和Chen-Kiang博士的指导下，开发和执行一项转化研究，以评估选定的有前途的药物在治疗多发性骨髓瘤中的效果。 2)与Scott Wadler博士一起进行临床试验设计的教学和指导培训，以及通过几个机构资源，包括一般临床研究中心和康奈尔大学医学研究生院。 3)开发和执行使用新型药物和联合药物的骨髓瘤药物启动的临床试验。 Niesvizky博士的研究主要集中在药物开发方面。 在这个为期五年的综合计划之后，他将获得独立的临床研究技能，与基础科学合作者一起领导药物开发和其他骨髓瘤新疗法的转化研究计划。 预计这项工作将大大有助于这种疾病和其他B细胞恶性肿瘤患者的护理。